Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD
Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD
Recruiting · NCT07187830 · Registry updated 2026-10-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD | Body Weight, Chronic Disease, Digestive System Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, kidney disorder, kidney failure, liver disorder, metabolic disease, nutritional disorder, obesity disorder, overnutrition, urinary system disorder | Recruiting | Not stated | 2026-10-07 | NCT07187830 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novo Nordisk A/S | 181 |
| University of Alberta | 249 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mazankowski Alberta Heart Institute | Edmonton | Canada | 6 |